Supriya Lifescience Limited
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.
What Supriya files
- Investor Meet52
- Others44
- Updates18
- Important10
- Board Meeting10
- PPTs7
Supriya Lifescience reported strong Q1 FY27 revenue growth of 31% YoY to ₹189.75 Cr. However, EBITDA declined 8% to ₹47.46 Cr, and Profit After Tax (PAT) fell 31% to ₹24.04 Cr, with margins contracting. Europe (44%) and Asia (34%) were key revenue contributors, while Anesthetic (48%) remained the largest therapy...
**Business Performance:** Supriya Lifescience saw robust Q4 FY26 with Revenue up 50% YoY to Rs 276.53 Cr and PAT rising 47% YoY to Rs 74.23 Cr. For FY26, Revenue grew 19% to Rs 827.87 Cr and PAT was up 11% to Rs 209.12 Cr. Europe contributed significantly. **Growth Drivers or...
**Supriya Lifescience Q3FY26 & 9MFY26 Update:** 1. **Business Performance:** Strong Q3: Revenue up 11% YoY to ₹206.44 Cr, PAT +6% to ₹49.68 Cr (EPS ₹6.2). 9M Revenue +8% to ₹551.35 Cr, PAT ₹134.89 Cr (-2% YoY, EPS ₹16.8). Exports are key (82% of Q3 revenue, led by Europe & Asia)....
Supriya Lifescience reported strong Q2 performance with revenue up 20.3% YoY to 199.83 Cr and PAT rising 9.3% to 50.43 Cr. For the half-year, revenue grew 5.6% to 344.91 Cr, though PAT saw a slight dip of 6.1% to 85.22 Cr, reflecting some margin pressure. Europe and Asia continue as...
**1. Financial Highlights:** Q1 FY26 financial results show revenue decreased 9.7% YoY to ₹145.07 Cr. EBITDA saw a 17.3% YoY drop to ₹51.70 Cr, with margins contracting to 35.6%. Profit for the period fell 21.9% YoY to ₹34.79 Cr, and PAT margins compressed to 24.0%. **2. Strategic Initiatives & Growth...